Luis Umana
Medical Biochemical Genetics · Dallas, TXNPI 1710145362
Payments from drug & device makers
Across 154 payments — averaging $1729.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Swedish Orphan Biovitrum AB$265K
- Biomarin Pharmaceutical Inc.$479
- Sanofi-aventis U.S. LLC$300
- Amgen$177
- Takeda Pharmaceuticals U.S.A., Inc.$115
- Sanofi$85
- plus $164 from 5 others
What the payments were for
- Speaking & faculty fees$67551%
- Food & beverage$64549%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Swedish Orphan Biovitrum AB | 131 | $265,013 |
| Biomarin Pharmaceutical Inc. | 4 | $479 |
| Sanofi-aventis U.S. LLC | 1 | $300 |
| Amgen | 2 | $177 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $115 |
| Sanofi | 4 | $85 |
| Travere Therapeutics, Inc. | 3 | $74 |
| PTC Therapeutics, Inc. | 1 | $28 |
| Orchard Therapeutics North America | 1 | $26 |
| Shire North American Group Inc | 1 | $19 |
| Dexcom, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Palynziq$479
- ALDURAZYME$300
- Kuvan$229
- RAVICTI$120
How this compares
Too few medical biochemical genetics providers in Texasto place this figure against a meaningful peer group, so we don't.
Other medical biochemical genetics in Dallas
- Yishay Ben MosheHouston$149
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.